Galderma is a leading global skincare company offering a range of medical and consumer skin health solutions through three business units; aesthetics and prescription and consumer health.
Galderma is a focused skincare company with a comprehensive product portfolio, exceptionally strong brands and high customer loyalty. Through its focus on science-based solutions for skin health, it seeks to enhance the quality of people's lives.
Founded in 1981 as Galderma and operating under the name Nestlé Skin Health as a wholly owned subsidiary of Nestlé since 2014, the business was carved out by the consortium comprising EQT, GIC, Luxinva (a wholly-owned subsidiary of ADIA), PSP Investments and other renowned institutional investors in 2019.
The company oprates on a truly worldwide level with research and development centers and manufacturing sites located throughout Asia-Pacific, Europe, Middle-East, Africa, North and Latin America.
With its aesthetics business, Galderma aims to make a difference in the lives of its customers by providing effective and proven medical aesthetic solutions to help them look and feel their best. The prescription business offers solutions to dermatologists and healthcare professionals that help patients finding relief from the burden of skin diseases. The third business unit, consumer health, sells products that customers need to maintain a healthy skin throughout their lives, among others the Cetaphil product range.
Market trends and drivers
Galderma is a global business with a well-balanced portfolio of dermatology products, targeting sizeable end-markets with strong underlying growth. The aesthetics and consumer health markets show high single digit growth driven by fundamental drivers such as an increasing awareness for skin appearance / protection and continued product innovation. The prescription market is fundamentally attractive and stable with multiple opportunities for business development.
The consortium around EQT VIII intends to support Nestlé Skin Health in its next period of growth and innovation, leveraging EQT's long-term experience and industrial network. The strategy builds on accelerating growth further by building on the company's strong market position and brands in attractive markets.
Priorities will be 1) to invest in commercial excellence and drive innovation in collaboration with health case professionals in the Aesthetics unit; 2) to continue investments in R&D and business development to strengthen the Prescription division and leverage its best-in-class commercial platform; 3) to increase presence in the US, launch new products and focus on international expansion in the consumer health business.